Department of Renal Medicine, Royal Infirmary of Edinburgh, Edinburgh, Scotland, UK.
Kidney Int. 2013 Oct;84(4):637-8. doi: 10.1038/ki.2013.158.
The incidence of acute kidney injury (AKI) is increasing. It is now widely accepted that patients surviving an episode of AKI have a significant risk of progression to chronic kidney disease (CKD) and even end-stage renal failure. Zager and colleagues describe the role of endothelin-1 (ET-1) in the progression of AKI to CKD and provide a basis for the potential use of ET receptor antagonists as a therapeutic strategy in AKI.
急性肾损伤 (AKI) 的发病率正在上升。现在人们普遍认为，经历过 AKI 发作的患者有进展为慢性肾脏病 (CKD) 甚至终末期肾衰竭的重大风险。Zager 及其同事描述了内皮素-1 (ET-1) 在 AKI 进展为 CKD 中的作用，并为 ET 受体拮抗剂作为 AKI 治疗策略的潜在用途提供了依据。
